Cost and economic burden associated with caring for children with Down syndrome: a systematic review Authors: Jyothi Shetty, Ankitha Shetty, Suneel Mundkur, Sujata Shirodkar, Prashanthi Kamath, Elstin Anbu, Prachi Pundir, Shradha S Parsekar Published: 2025 ABSTRACT AbstractObjectiveTo summarise the direct and indirect cost incurred by the family and to evaluate the economic burden of caring for children with Down syndrome (DS).MethodsA systematic review was carried out following the Joanna Briggs guidelines. The English language studies published between 2000 and August 2024 were searched in seven databases, grey literature sources and references of the included studies. The studies were included if they assessed the cost of caring for DS children (< 18 years) or described the perception of the parents regarding the financial burden. This review included observational, longitudinal, mixed-methods and qualitative studies. Two reviewers independently screened the studies, extracted the data using a custom-made form and assessed the critical appraisal using JBI checklists. The mean and/or median costs were inflated to January 2025 and reported in US$, and the data were narratively synthesised. Thematic analysis was performed for the qualitative data.ResultsThe search retrieved 5652 records, of which 24 studies were included. A consistent higher cost was reported for DS children as compared with non-DS children, eg, cost associated with prescription drug claims was six times higher (US$2869 vs US$413, respectively). Additionally, there was a higher cost of caring for DS infants (eg, US$3453) as compared with the older (13–17 years: US$1157) DS children. Qualitative findings suggest that families incur additional medical, education and rehabilitation expenses, resulting in financial burden.ConclusionConsidering the higher financial burden, the creation of an appropriate system of care and support mechanisms may alleviate the burden and reduce the cost of healthcare. Findings highlight the gap in research and need for standardised approaches to cost evaluation.PROSPERO registration numberCRD42021265312.Keywords: Caregivers, Health services research WHAT IS ALREADY KNOWN ON THIS TOPIC There is a paucity of literature regarding the assessment of the global economic burden of Down syndrome and cost of caring for individuals with the condition. There is a paucity of literature regarding the assessment of the global economic burden of Down syndrome and cost of caring for individuals with the condition. WHAT THIS STUDY ADDS The cost of managing children with Down syndrome is two to six times higher compared with children without Down syndrome and is particularly three to six times higher in infants than older children or adolescents with the condition. The cost of managing children with Down syndrome is two to six times higher compared with children without Down syndrome and is particularly three to six times higher in infants than older children or adolescents with the condition. HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY Implementing subsidised and affordable pricing strategies is essential to boost the quality of life of families with children with Down syndrome and reduce the economic burden faced by the family. Implementing subsidised and affordable pricing strategies is essential to boost the quality of life of families with children with Down syndrome and reduce the economic burden faced by the family. Introduction Down syndrome (DS) is the most common cause of lifelong intellectual disabilities, contributing to 15–20% of the intellectual disability globally.1 The global live birth incidence of DS is 1 in every 700–800 live births.2 The individuals with DS experience cognitive impairment, delayed development and physical and social issues.2 Many DS individuals are vulnerable to comorbidities and chronic physical diseases, which increases their requirement for highly specialised care3 and dependence on others.3 4 Advances in the healthcare system have significantly improved the life expectancy of individuals with DS who are now living well into their 50 s and beyond, especially in high-income countries (HICs).5 However, this increased longevity creates a sustained demand for specialised medical care, inclusive education and social support, placing a considerable burden on the families and caregivers.6,9 Additionally, hospitalisations, use of invasive therapies and surgeries, and other costs and care drain the caregivers financially.10 Furthermore, family burden gets compounded by investing a considerable amount of time caring for children with DS, which in return can affect their economic resources.3 Despite the rising concern among caregivers, the literature is fragmented and there is a need to provide comprehensive evidence; hence, we carried out this systematic review. The primary objective is to summarise the direct and indirect costs incurred by the family in taking care of the children with DS. Additionally, to synthesise and evaluate the current evidence of the economic burden experienced by the family of DS children. Materials and methods A detailed methodology can be found in a published protocol6 and in online supplemental file 1; here we briefly describe it. Registration and reporting The review is conducted as per Joanna Briggs Institute (JBI) manual and reported following the requirements of Preferred Reporting Items for Systematic Reviews and Meta-Analysis 2020 (PRISMA- 2020).11 The protocol was registered in PROSPERO (CRD42021265312) and published in a peer-reviewed journal.6 Eligibility criteria Study design Observational and qualitative studies assessing direct or indirect cost incurred by the families with focus on the economic burden of the caregivers of DS children were included. Economic evaluations of interventions and interventional studies were excluded. Type of participants Participants were the adult informal caregivers or the parents of DS children aged 0–18 years. If there was no subgroup analysis for the population of our interest, we included studies having at least 90% of the population with DS children. Types of outcomes The outcomes listed below were eligible to be included. Direct costs included the value of all the resources that are consumed in the provision of the treatment and care to the DS individuals. The costs could be measured as standalone or combined and reported in monetary terms. The costs could be directly reported by the family or were extracted from the claims database and hospital records. There was no restriction whether the society, individual or healthcare perspective was captured. Direct costs included the value of all the resources that are consumed in the provision of the treatment and care to the DS individuals. The costs could be measured as standalone or combined and reported in monetary terms. The costs could be directly reported by the family or were extracted from the claims database and hospital records. There was no restriction whether the society, individual or healthcare perspective was captured. Indirect costs such as the productivity losses related to the illness and the inability to work (morbidity costs) associated with taking care of DS children. Indirect costs such as the productivity losses related to the illness and the inability to work (morbidity costs) associated with taking care of DS children. Informal caregivers’ financial burden expressed as financial strain or stress, and economic burden measured quantitatively using any standard tools or definitions, either using a single item or a composite score. Informal caregivers’ financial burden expressed as financial strain or stress, and economic burden measured quantitatively using any standard tools or definitions, either using a single item or a composite score. The qualitative data describing financial burden expressed by the participants. The qualitative data describing financial burden expressed by the participants. Language, publication type and timeline considered English publications, published between the year 2000 and August 2024, to highlight the latest data on cost and financial burden. We included studies published in journal publications, reports, working papers, theses or dissertations irrespective of their peer review status. Search and search strategy Electronic database searches The searches were conducted in Medline (via PubMed), Cochrane (Wiley), Scopus (Elsevier), Web of Science (Clarivate), EMBASE (Elsevier), CINAHL and ProQuest. The search strategy was designed by the trained team member and reviewed by another team member. The search strategies can be found in the online supplemental file 2.1. Searches in other sources We explored websites of different organisations on 29 and 30 July 2024 to identify grey literature. The names of various websites and their links can be found in online supplemental file 2.2. Furthermore, the first 10 pages of Google Scholar were searched on 30 July 2024 and repeated on 25th January 2025 to identify any potential records. Additionally, the references of included studies were scanned. Study selection The search yield from the electronic databases and other sources was merged and deduplicated using EndNote X7. Titles and abstracts were independently screened by two authors. The full texts were retrieved and read independently by the two authors. Any disagreement was discussed with the third reviewer and consensus was reached. Detailed records at every stage, including reasons for exclusion, were documented and reported in the PRISMA 2020 flow diagram.11 Data extraction Data extraction was performed independently by two authors using a piloted data extraction sheet. Disagreements were discussed between two reviewers, and a third reviewer examined the extracted data and gave a final decision. Critical appraisal of included studies Two reviewers independently assessed risk of bias of included studies. In the case of disagreements, it was discussed with a third reviewer (SP) and consensus was reached. All included studies were critically appraised using Critical Appraisal tools for use in ‘JBI Systematic Reviews’. Depending on the type of study, we used three different types of checklists.12 Each question in the tool consisted of four options, namely yes, no, unclear and not applicable. Data synthesis Direct and indirect cost The currencies were converted to US$ prior to calculating the inflation, costs were inflated to January 2025 and reported in US$ using the Consumer Price Index. Due to heterogeneity in the cost data, healthcare systems, government support, cultural norms and social care structures across countries, we presented the data in tables and descriptively summarised it as per outcomes and perspectives, whether studies reported it explicitly or not. We operationalised the family perspective when all the costs were borne by the DS patients and their family members. Society’s perspective is when all the costs were borne by the entire society. Furthermore, the health system perspective consists of a collection of actions whose main purpose is to improve health and it includes direct, market-valued costs, whether public or private, that are needed to deliver the intervention, regardless of the payer. This also covers the payments made by health service users out-of-pocket; however, it does not include patients’ direct non-medical costs such as travel-related costs and productivity costs.13 Furthermore, this review did not assess publication bias and quality of evidence. Economic burden The economic burden was reported in a variety of ways; hence, we descriptively summarised the findings. The effect estimates such as mean, mean difference, OR and risk ratio with a 95% CI were captured as documented by the included studies. Thematic analysis was performed for the data arising from qualitative studies. Patient and public involvement Patients and public were not directly involved during the review process. Amendments from protocol The following amendments were made from protocol to review stages: Age groups. We restricted the age group of DS children to 18 years of age. Age groups. We restricted the age group of DS children to 18 years of age. Studies such as secondary data analysis reporting costs incurred by the family or household available from insurance claims, hospital records or other databases were included. These studies might not have recruited caregivers for data collection. Studies such as secondary data analysis reporting costs incurred by the family or household available from insurance claims, hospital records or other databases were included. These studies might not have recruited caregivers for data collection. We included qualitative studies reporting perspectives of informal caregivers on the financial or economic burden of caring for the children with DS. We included qualitative studies reporting perspectives of informal caregivers on the financial or economic burden of caring for the children with DS. EconLit was not searched due to accessibility issues. EconLit was not searched due to accessibility issues. Critical appraisal was carried out by using the critical appraisal tools for use in JBI systematic reviews. Critical appraisal was carried out by using the critical appraisal tools for use in JBI systematic reviews. Results Study selection We identified a total of 5644 records from the electronic searches from different databases and registers. An additional 18 records were identified from citation searching. After removing duplicates (n=1612), 4032 records were screened for titles and abstracts. Of these, 59 abstracts were subjected to full-text screening. We included a total of 24 studies in our review (figure 1 for the PRISMA flow diagram). A list of excluded studies at full texts can be found in the online supplemental file 3. PRISMA 2020 flow diagram for new systematic reviews which included searches of databases, registers and other sources. Source: Page et al.11 Characteristics of included studies Cost-related studies The studies (online supplemental file 4.1) were published between 2008 and 2019 and the year of data collection ranged from 1999 to 2015. Four studies were from the USA, and one each from Mexico, China, Taiwan, Australia and Korea. Four studies included children and young adults,14,17 and the rest were exclusively conducted among children. The studies reported various outcomes; see section 3.4 for more details. The other outcomes were prevalence of DS,18 19 life expectancy and survival rates for individuals with DS,14 length of hospital stay,16 20 21 households with catastrophic expenditure and time spent caring,22 and mortality.20 Quantitative studies reporting economic burden A total of eight cross-sectional quantitative studies reported economic burden (See online supplemental file 4.2). Five studies were based on primary data sources exclusively conducted among children. Three studies were reported from the USA, and one each from Slovakia, Türkiye, Iran, Morocco and Nepal. Studies reported various outcomes, of which financial stress or strain was majorly reported.23,25 Qualitative studies A total of six qualitative studies and one mixed methods study were included (online supplemental file 4.3). These studies were reported one each from Canada, the USA, Iran, Saudi Arabia, Kuwait, Indonesia and Ireland. The studies reported various themes, such as support mechanisms, system gaps and needs, personal impacts and financial burden. Critical appraisal of included studies Studies reporting prevalence Included four studies.14 19 20 24 One study20 reported adequacy of the sample size. Except one,24 the other three studies measured the condition as per acceptable standards for all participants (online supplemental file 5.1). Analytical cross-sectional studies Included 14 studies.15,1821 Six studies2325,27 29 30 did not provide sufficient explanation on whether objective or standard diagnostic criteria were used for measurement of the condition. In five studies,21 23 25 29 30 actions taken to manage the confounding factors were not dealt with or reported. Four studies2327,29 did not clearly specify whether the outcomes were measured using valid and reliable methods (online supplemental file 5.2). Studies reporting qualitative data Included seven studies.31,37 One33 was found to report the researcher’s cultural background. One study32 described the researcher’s positionality. Two studies33 35 did not provide any information on the ethical clearance from any institution (online supplemental file 5.3). Costs associated with caring for children with DS We grouped various costs associated with healthcare services as healthcare cost and cost associated with living. Most studies considered direct healthcare costs; hence, we did not report disaggregated results for direct and indirect costs. However, if available, indirect costs are explicitly stated in our synthesis. Healthcare-related costs The total healthcare cost (table 1) varied between LMIC (Mexico US$39.28) and HIC (USA US$3247) for infants with DS. For children, 0–4 years, the average healthcare cost was $3474 in Australia. Inpatient cost (table 2) ranged from US$104 to US$36 729 for preschoolers or younger children in the USA, and in China it was US$619. A study from China reported the surgery cost as US$1344 (table 2). The outpatient service cost (table 3) ranged from US$242 (China) to US$22 851 (USA) in DS children under 6 years. The pharmaceutical cost was higher for younger compared with older children with DS in Australia. The cost associated with prescription drug claims was six times higher (US$2869 vs US$413) for infants with DS compared with non-DS children from the USA. Direct diagnosis cost (US$190) and indirect cost (US$173) associated with diagnosis were reported as higher in 0 to 6 years, with respect to societal perspective, by a study conducted in China (table 4). The detailed synthesis of healthcare-related costs can be found in online supplemental file 6. Table 1Total healthcare costStudy ID (country)Outcome detailsAge in yearsGroup 1: children with DSGroup 2 details, if anyGroup 1 cost (2025)Group 2 cost (2025)Health system perspectiveGeelhoed et al15 (Australia)Total mean healthcare cost0–4n=58NAAverage (A): 3474NA5–9n=75NAA: 172NA10–14n=86NAA: 1247NA15–19n=81NAA: 1099NA5–14n=161Australian population, n=NRMean (M): 1468NAUnreported perspectiveKageleiry et al17 (USA)Total annual costChildren with DSChildren with no chromosomal conditions0–<1n=1371n=5484A: 3453A: 8251–<3n=1457n=5828A: 2792A: 4863–<5n=1407n=5628A: 2101A: 3615–<13n=2126n=8504A: 1691A: 35013–<18n=1334n=5336A: 1157A: 419Kageleiry et al17 (USA)Total medical cost Children with DSChildren without any chromosomal conditions0–<1n=1371n=5484A: 3248A: 7591–<3n=1457n=5828A: 251A: 4203–<5n=1407n=5628A: 1868A: 2955–<13n=2126n=8504A: 1437A: 27013–<18n=1334n=5336A: 87A: 318Martínez-Valverde et al22 (Mexico)Annual out-of-pocket medical care expenditures*0–<1Children with DSNAMedian (Md): 39NA1–5NAMd: 30NA> 5NAMd: 66NA*Defined as direct disbursements for the medical needs of the child with DS during the appointment at the HIMFG, such as medications, outpatient visits, prostheses, lab tests, clinical analyses and hospitalisations.A, average; DS, Down syndrome; M, mean; Md, median; NA, not available; NR, not reported. Total healthcare cost Defined as direct disbursements for the medical needs of the child with DS during the appointment at the HIMFG, such as medications, outpatient visits, prostheses, lab tests, clinical analyses and hospitalisations. A, average; DS, Down syndrome; M, mean; Md, median; NA, not available; NR, not reported. Table 2Inpatient and surgical costStudy ID (country)Outcome detailsAge in yearsGroup 1: children with DSGroup 2 details, if anyGroup 1 cost (2025)Group 2 cost (2025)Inpatient cost with family perspectiveChen et al14(China)Direct IP cost0–6n=40NAA: 619NAIndirect IP cost0–6n=40NAA: 113NAInpatient cost with societal perspectiveChen et al14(China)Direct IP cost0–6n=40NAA: 693NAIndirect IP cost0–6n=40NAA: 378NAInpatient cost with health systems perspectiveGeelhoed et al15 (Australia)Hospital care cost0–4n=58NAM: 1420NA5–9n=75NAM: 313NA10–14n=86NAM: 428NA15–19n=81NAM: 185NAInpatient cost with unreported perspectiveBoulet et al19 (USA)Average component costs of IP except first 4 days of birth hospitalisationChildren with DSChildren without DS0–4n=144n=18 911M: 36 729M: 2051<1n=73n=11 799M: 114 865M: 77891–2n=50n=4614M: 2136M: 6703–4n=21n=2498M: 3570M: 295Derrington et al21 (USA)IP cost from birth0–3n=504n=4 68 600M: 34 945M: 5754IP costs: birth to 3 yearsM: 32 421M: 1815IP cost: birth to post-birthM: 67 366M: 7570Hung et al16 (Taiwan)Hospital admission expenses<20n=250NATotal medical cost: 2668NAKageleiry et al17 (USA)IP costChildren with DSChildren without any chromosomal conditions0–<1n=1371n=5484M: 1630M: 3561–3n=1457n=5828M: 661M: 883–<5n=1407n=5628M: 567M: 455–<13n=2126n=8504M: 37M: 4613–<18n=1334n=5336M: 257M: 59Kageleiry et al17 (USA)Emergency room cost0 –<1n=1371n=5484M: 146M: 601–3n=1457n=5828M: 104M: 713–<5n=1407n=5628M: 77M: 495–<13n=2126n=8504M: 56M: 3713–<18n=1334n=5336M: 49M: 37Dawson et al20 (USA)Birth IP cost0–10n=2366NAM: 31 429NApost-birth (<1 year) IP cost0–10n=1149NAM: 55 696NASurgery/operation cost reported with a society perspectiveChen et al14 (China)Direct operation cost0 to 6n=40NAA: 1344NASurgery/operation cost reported with a family perspectiveChen et al14 (China)Direct operation cost0 to 6n=40NAA: 1344NAA, average; DS, Down syndrome; IP, inpatient; M, mean; NA, not available; NR, not reported. Inpatient and surgical cost A, average; DS, Down syndrome; IP, inpatient; M, mean; NA, not available; NR, not reported. Table 3Outpatient costStudy ID (country)Outcome detailsAge in yearsGroup 1: children with DSGroup 2 details, if anyGroup 1 cost (2025)Group 2 cost (2025)Outpatient cost reported with a societal perspectiveChen et al14 (China)Direct outpatient cost0–6n=40NAA: 242NA7–18n=107NAA: 415NAIndirect outpatient cost0–6n=40NAA: 11NA7–18n=107NAA: 19NAOutpatient cost reported with a family perspectiveChen et al14 (China)Direct outpatient cost0–6n=40NAA: 242NA7–18n=107NAA: 415NAIndirect outpatient cost0–6n=40NAA: 22NA7–18n=107NAA: 64NAGeelhoed et al15 (Australia)Total mean cost of medical care (GP and specialist)0–4n=58NAM: 284NA5–9n=75NAM: 270NA10–14n=86NAM: 206NA15–19n=81NAM: 174NAOutpatient cost with unreported perspectiveChildren with DSChildren without DSBoulet et al19 (USA)Average component costs of outpatient services0–4n=420n=3 15 283M:22 851M: 2743<1n=97n=72 109M: 27 625M: 57071–2n=176n=1 19 561M: 24 371M: 24813–4n=147n=1 23 613M: 17 884M: 1432Kageleiry et al17 (USA)Outpatient costChildren with DSChildren with no chromosomal abnormalities0–<1n=1371n=5484M: 971M: 3191–<3n=1457n=5828M: 1097M: 2383–<5n=1407n=5628M: 913M: 1895–<13n=2126n=8504M: 770M: 17513–<18n=1334n=5336M: 457M: 205*Outpatient visits were calculated based on the number of days outpatient claims were reported; outpatient provider visits, as well as emergency department visits, were included in this variable.A, average; DS, Down syndrome; M, mean; NA, not available; NR, not reported. Outpatient cost Outpatient visits were calculated based on the number of days outpatient claims were reported; outpatient provider visits, as well as emergency department visits, were included in this variable. A, average; DS, Down syndrome; M, mean; NA, not available; NR, not reported. Table 4Pharmaceutical and diagnosis costStudy ID (country)Outcome detailsAge in yearsGroup 1: children with DSGroup 2 details, if anyGroup 1 cost (2025)Group 2 cost (2025)Drug/Medicine cost reported with health systems perspectiveGeelhoed et al15 (Australia)Pharmaceutical care cost0–4n=58NAM: 51NA5–9n=75NAM: 77NA10–14n=86NAM: 36NA15–19n=81NAM: 35NADrug/Medicine cost with unreported perspectiveBoulet et al19 (USA)Average component costs associated with prescription drug claimsChildren with DSChildren without DS0–4n=364n=2 43 238M: 1558M: 313< 1n=86n=52 977M: 2869M: 4131–2n=153n=96 051M: 1328M: 3093–4n=125n=94 210M: 966M: 260Kageleiry et al17 (USA)Total pharmacy costChildren with DSChildren without chromosomal conditions<1n=1371n=5484M: 205M: 65<3n=1457n=5828M: 277M: 66<5n=1407n=5628M: 231M: 66<13n=2126n=8504M: 255M: 81<18n=1334n=5336M: 282M: 100Diagnosis cost reported with a society perspectiveChen et al14 (China)Direct diagnosis cost0–6n=40NAA: 191NAIndirect cost diagnosis cost0–6n=40NAA: 173NADiagnosis cost reported with a family perspectiveChen et al14 (China)Direct diagnosis cost0–6n=40NAA: 35.31NAIndirect cost associated with diagnosis0–6n=40NAA: 19.53NAA, average; DS, Down syndrome; M, mean; NA, not available; NR, not reported. Pharmaceutical and diagnosis cost A, average; DS, Down syndrome; M, mean; NA, not available; NR, not reported. Living and education costs Rehabilitation cost was found to be US$812. Average expenses for transportation for surgery (US$89) in 0 to 6 years were the highest, followed by transportation during rehabilitation (US$53) in 7 to 18 years. Average expenses for accommodation during inpatient admission were US$134. Average expenses for rehabilitation were US$79 for all the age groups. Average expenses for nutrition and health products were US$226 for all the age groups. Expenses for accompanying service in the 7 to 18 years age group were US$8892. The above expense was reported by a single study conducted in China. Whereas, home health agency cost as well as home health agency third party insurer cost was more in one to <3 years of children with DS amounting to US$609 and US$3745, respectively (n=1 study conducted in the USA). Special education expenses were highest (US$3588) for the 7 to 18 years age group (n=1 study, China). Indirect costs associated with daycare services for the 7 to 18 years age group were found to be the highest (US$14 645) (n=1 study, China). The mean total other costs were found to be US$1726.4148, which was highest for 0 to 4 years (n=1 study, Australia). While in another study from the USA, it was highest in 1 to <3 years of children with DS, amounting to US$45.474. The detailed synthesis of living and education costs can be found in online supplemental file 7. Economic burden of caring for children with DS Findings from quantitative studies Studies reported the proportion of participants experiencing economic burden.23,2527 29 The definitions and the tools used to assess burden varied. Financial burden was a single item as part of measuring overall burden. The proportions of caregivers reporting financial burden varied between these studies. A study from Türkiye documented that 22.3% of the study participants experienced economic problems considering DS’s special education and medical needs.23 In studies conducted in Morocco24 and the USA,27 the proportions of caregivers experiencing economic burden were 28% and 29.7%, respectively. Furthermore, a study conducted in low resource settings ie, Nepal, found that more than half (55.2%) of caregivers felt that they always experienced economic burden and one-fifth (19.8%) reported that sometimes they experienced economic burden.29 Contrastingly, a study conducted in Slovakia reported fractional per cent (6%) of caregivers reporting economic burden.25 Furthermore, a study from the USA reported that 29% of caregivers had to rely on an additional source of income to cover the medical expenses of the children with DS, approximately two-fifths (42.3%) discontinued working and one-third (34.9%) reduced hours of working due to the child’s health condition, further compounding economic burden.27 The rest of the studies reported factors associated with burden.26 28 30 The parents with lower incomes from Iran and the USA had higher burden or stress.26 30 However, these should be interpreted with caution as the burden was not explicitly stated as a financial burden. Another study from the USA reported that families with DS children had 1.8 times higher odds of experiencing economic burden compared with families having children with other special healthcare needs. Furthermore, a study found that the caregivers had three times higher odds of reducing work hours or discontinuing work as compared with the comparator group. Nevertheless, access to medical homes lessened the burden experienced by family members caring for children with DS.28 Findings from qualitative studies Children with DS have additional medical, educational, speech and rehabilitation needs, resulting in a high cost of care. The cost of special schools, the cost of occupational therapy and speech therapy is high; most often it was out-of-pocket expenditure.33,35 The findings from qualitative studies also suggest that some parents quit their jobs to take care of their children, compounding their financial situation. Especially single mothers or single working parents experienced high financial burden. Financial hardship also affected families who have children in addition to the DS child.35 The financial burden of a working parent subsequently led to emotional stress36 and influenced marital relationships.32 Participants in the studies also expressed that the cost of managing children with DS increased as they grew older.35 In Saudi Arabia, DS children receive some discounts on rehabilitation and treatment charges by the government, and the USA receives disability tax credit and insurance covers the cost if the parent and child are insured. However, caregivers suggested that the benefits should be increased considering the high cost of treatment and rehabilitation needs of the children, especially those who live far from the healthcare centres.31 33 The caregivers who themselves suffer from medical issues felt the additional need for monthly allowances to support them.33 In contrast, a study from Kuwait suggested that participants were satisfied with the financial support provided by the government to meet the needs of persons with DS.37 Discussion Discussion of key findings Our systematic review addresses a previously unexplored area by assessing the costs related to DS. Our findings suggest that healthcare expenditure is high overall for DS children as compared with children without DS. The healthcare cost (eg, total healthcare expenses, inpatient cost) was higher during infancy as compared with older DS children. The healthcare cost reported by studies conducted in the USA19,21 and Taiwan16 was comparatively higher than studies conducted in other countries. The other predictors for higher cost were being males and having congenital heart diseases. The variations in government policies and programmes, insurance status, social protection schemes and cultural beliefs influence the healthcare spending and cost burden on families. These could be some of the reasons for cost differences in reported studies. The cost of management for children with DS decreased with the increasing age of the child. This pattern was observed in other disorders such as autism.38 Younger children often require more frequent medical visits, diagnostic tests and intensive early interventions such as speech, occupational and physical therapies. As children grow older, their health needs often stabilise or parents and caregivers become more adept at managing their child’s condition.39 This may not hold true for DS with comorbidities and chronic physical diseases, and there is a need for more research on this topic. The healthcare-related costs, such as the total, inpatient, outpatient, drug/medicine, diagnosis and surgery/operation costs, were reported often in multiple studies. Fewer studies mention indirect costs compared with direct costs. This suggests that indirect costs might have been overlooked; however, these are important to provide a complete picture of the economic impact. We could not pool the cost data due to inconsistencies in the reported data. Some studies reported mean cost, whereas others reported median or total costs, and there were variations in definitions of the cost, the included ages of children with DS, country context and social support system. For most outcomes, a smaller number of studies was available. Hence, sub-group analysis was not possible. The above differences limited the comparability of results across countries. Hence, our synthesis described patterns and ranges rather than drawing direct quantitative comparisons. A deviation from the protocol, under the costs, we summarised the studies according to different perspectives shared in the included study. We looked at individual or familial, societal and health systems perspectives and carried out the analysis despite variability. Each perspective captured unique aspects of the cost data, such as out-of-pocket expenses for individuals and families, broader economic impacts on society and resource allocation within health systems. Although many of the studies had an unclear perspective, as anticipated, our analysis revealed a smaller number of studies examining health systems. There was a notable variation in tools used to measure financial burden. This variation highlights inconsistencies in the methodology across studies and the lack of standardisation, leading to challenges in comparing results between studies. Financial burden was a sub-part of overall burden, and multiple studies were excluded because they did not consider financial burden in the overall assessment of burden. With a proportion of nearly 30% of the parents or caregivers in HICs and more than 55% of the parents or caregivers in LICs experiencing economic burden, our qualitative and quantitative findings highlighted that families experience high financial burden while taking care of their DS children. We found that DS research is predominantly concentrated in HICs. HICs typically have more financial resources allocated to medical research, supported by government agencies, private institutions and non-profit organisations, which may be one of the common reasons for more studies in these regions. Another reason can be the robust systems for collecting and maintaining health data in HICs or the presence of frameworks, guidelines or standards that help maintain the integrity and ethical conduct of research.40 HICs benefit from robust databases and registries for various diseases and conditions, facilitating comprehensive health data analysis. In contrast, low- and lower-middle-income countries (LIC & LMICs) often lack such infrastructure, which hampers effective health data analysis and diseases, such as DS, likely to receive low priority. This disparity underscores the need for developing similar databases in LMICs, particularly for conditions like DS. Strengths and limitations The review included extensive evidence on direct healthcare and other services costs incurred by individuals with DS and their caregivers. Further, this review is supplemented by synthesising financial burden expressed in quantitative and qualitative data. The review tried to minimise bias by adhering to standard procedures mentioned in the JBI manual; eg, independently screening, data extraction and critical appraisal of included studies. Despite these, there are a few limitations. The search was restricted to English language publications. The database such as EconLit was not searched as it was not accessible. Nevertheless, we tried to make the search extensive by including multiple electronic databases and grey literature sources. Furthermore, heterogeneity in methods, outcome definitions, demographic characteristics and country context restricted pooling the results statistically. Recommendations for research There is a paucity of literature on financial burden and commonalities in measuring financial burden. Tools to measure can be worked on. The majority of the studies were conducted in HICs; more research is needed from LMICs and LICs. Perspectives should be included in the future research and the studies should report from which perspective cost was assessed. Studies with a broader societal perspective could significantly improve health system resource allocation. More studies should be carried out on the societal perspective as it is necessary for an optimal allocation of resources for the treatment of DS patients as well as for the betterment of patient care. Studies should be clearer about the different types of costs that are grouped to form cost categories, such as direct and indirect costs and their computation methods. Studies should also disintegrate the different components of direct costs, which in turn will help decision makers to allocate the budgets under which the main financial burden falls. Recommendations for clinical practice To address the economic burden, particular strategies need to be planned at the health systems and family level. Financial protection schemes such as issuing of a health insurance card by the government and having a planned institutional care/daycare facility at a subsidised and affordable price are required to protect DS families from catastrophic expenditure and to improve the quality of life. The government can consider creating support groups to empower DS individuals and decide on occupational and rehabilitation based on the level of their disability to improve their self-sufficiency. Based on review findings, we conclude that creating a standardised framework which has been internationally agreed for future costing exercises focusing on DS is needed. These efforts should permit vigorous comparisons across countries globally, providing recommendations for health system research allocation. Conclusion The review findings highlight the critical need for DS economic burden research in low- and lower-middle income countries, where data are often scarce. Future research should incorporate diverse perspectives to provide a comprehensive understanding of the financial impacts on caregivers of children with DS. Additionally, implementing subsidised and affordable pricing strategies are essential to boost the quality of life of families with DS children and reduce their economic burden. Supplementary material Acknowledgements Authors would like to acknowledge Dr Ranjana Rao, intern, Collaboration for Evidence Synthesis, for providing support in critical appraisal of some of the included studies. Footnotes Funding: The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors. Provenance and peer review: Not commissioned; externally peer reviewed. Patient consent for publication: Not applicable. Ethics approval: Not applicable. Patient and public involvement: Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research. Data availability statement All data relevant to the study are included in the article or uploaded as supplementary information. References Supplementary Materials Data Availability Statement All data relevant to the study are included in the article or uploaded as supplementary information.